[2] PhotoMedex to Present At American Electronics Association Financial Conference November 7-8, 2000.

Business Editors

AEA Classic 2000

RADNOR, Penn.--(BUSINESS WIRE)--Nov. 3, 2000

PhotoMedex, Inc. (Nasdaq: PHMD) today announced that it is a participant in the American Electronics Association (AEA) Thirtieth Annual Financial Conference for Public Technology Companies to be held at the Sheraton Hotel and Marina in San Diego, CA on November 5-8, 2000.For 57 years the AEA has been the leading high-tech trade association in the nation. This 2000 financial conference celebrates 30 years of high-tech success and has been dubbed the AEA CLASSIC in honor of that distinction. The AEA Classic will showcase over 300 public technology member companies from $100 Million to over $10 Billion market cap or sales. During this prestigious conference, AEA member companies will be presenting to more than 1200 key technology investors. The Classic provides companies a platform to showcase their management teams, company positioning and technology news.

The Company will be giving multiple presentations over the course of two days on November 7-8, 2000.

Jeff O'Donnell, President and CEO of PhotoMedex, commented, "We are pleased to be a participant in the AEA Classic financial conference. The additional exposure we will receive from such a highly regarded technology event can only help in our goal of becoming a major medical device company."

The Company's excimer laser system generating 308-nm UV-B radiation is the first FDA-approved laser treatment for psoriasis, which is the second most common skin disorder in the U.S. The National Psoriasis Foundation estimates that psoriasis afflicts more than 7 million Americans and that between 150,000 and 260,000 new cases are diagnosed each year.

PhotoMedex is engaged in the development of proprietary excimer laser and fiber optic systems and techniques directed toward dermatological applications focusing on psoriasis, and toward the treatment of cardiovascular and vascular disease.

Some paragraphs of this press release, particularly those describing PhotoMedex' strategies, operating expense reductions and business plans, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1993, as amended and Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While PhotoMedex is working to achieve those goals, actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including difficulties in marketing its products and services, need for capital, competition from other companies and other factors, any of which could have an adverse effect on the business plans of the subsidiary companies of PhotoMedex, its reputation in the industry or its expected financial return from operations. Factors such as these could have an adverse effect on PhotoMedex' results of operations. In light of significant uncertainties inherent in forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by PhotoMedex and its subsidiaries that it will be achieved